Catalyst Pharmaceuticals, Inc.
CPRX
$23.10
$0.482.12%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.25% | 3.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.25% | 3.64% | |||
| Cost of Revenue | 1.36% | 14.56% | |||
| Gross Profit | 1.23% | 1.65% | |||
| SG&A Expenses | 3.31% | -2.05% | |||
| Depreciation & Amortization | 0.00% | -0.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.32% | 2.83% | |||
| Operating Income | -0.05% | 4.63% | |||
| Income Before Tax | 2.51% | -2.80% | |||
| Income Tax Expenses | 6.21% | 18.12% | |||
| Earnings from Continuing Operations | 1.30% | -8.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.30% | -8.16% | |||
| EBIT | -0.05% | 4.63% | |||
| EBITDA | -0.10% | 4.02% | |||
| EPS Basic | 0.94% | -8.69% | |||
| Normalized Basic EPS | 0.87% | 4.64% | |||
| EPS Diluted | 2.44% | -8.89% | |||
| Normalized Diluted EPS | 1.58% | 4.76% | |||
| Average Basic Shares Outstanding | 0.36% | 0.57% | |||
| Average Diluted Shares Outstanding | -0.36% | 0.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||